Full text is available at the source.
YN1548: A novel small-molecule agonist of human glucagon-like peptide-1 receptor for the treatment of type 2 diabetes mellitus and obesity
YN1548: A new small drug that activates the human GLP-1 receptor to help treat type 2 diabetes and obesity
AI simplified
Abstract
YN1548 demonstrated a half-maximal effective concentration of 4.59, 24.28, and 2.20 nM for activating the human GLP-1 receptor.
- YN1548 shows potent binding to the human GLP-1 receptor, activating the cAMP signaling pathway.
- Maximal efficacy of YN1548 ranged from 101.0% to 103.9%, comparable to the natural GLP-1 (7-36) amide.
- The compound exhibited biased agonism, favoring cAMP response over β-arrestin recruitment.
- Pharmacokinetic studies suggest that YN1548 is suitable for oral administration.
- In diabetic monkeys, oral YN1548 reduced blood glucose levels and enhanced insulin secretion in a concentration-dependent manner.
- YN1548 also led to reduced food intake and induced weight loss similar to that seen with liraglutide.
AI simplified